Ubs Group Ag An2 Therapeutics, Inc. Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 56,694 shares of ANTX stock, worth $64,631. This represents 0.0% of its overall portfolio holdings.

Number of Shares

56,694

Previous 62,000 8.56%

Holding current value

$64,631

Previous $65,000 10.77%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$1.05 - $1.34 $5,571 - $7,110	-5,306 Reduced 8.56%	56,694 $72,000
Q2 2025 Aug 14, 2025	SELL	$1.06 - $1.4 $46,662 - $61,629	-44,021 Reduced 41.52%	62,000 $65,000
Q1 2025 May 13, 2025	SELL	$1.07 - $1.52 $68,769 - $97,691	-64,271 Reduced 37.74%	106,021 $144,000
Q4 2024 Feb 14, 2025	BUY	$1.0 - $1.67 $170,292 - $284,387	170,292 New	170,292 $231,000
Q2 2024 Aug 13, 2024	SELL	$1.93 - $3.76 $4,035 - $7,862	-2,091 Reduced 10.68%	17,483 $37,000

Q1 2024 May 13, 2024	BUY	$2.78 - $21.53 $54,415 - $421,428	19,574 New	19,574 $63,000
Q3 2023 Nov 09, 2023	SELL	$7.58 - $16.08 $65,392 - $138,722	-8,627 Reduced 17.37%	41,046 $660,000
Q2 2023 Aug 11, 2023	SELL	$5.06 - $9.91 $12,913 - $25,290	-2,552 Reduced 4.89%	49,673 $422,000
Q1 2023 May 12, 2023	BUY	$7.94 - $15.6 $6,113 - $12,012	770 Added 1.5%	52,225 $515,000
Q4 2022 Feb 08, 2023	BUY	$8.51 - $19.69 $190,181 - $440,032	22,348 Added 76.78%	51,455 $490,000
Q3 2022 Nov 10, 2022	SELL	$7.61 - $22.29 $146,568 - $429,305	-19,260 Reduced 39.82%	29,107 $506,000
Q2 2022 Aug 10, 2022	BUY	$7.7 - $18.82 $363,509 - $888,473	47,209 Added 4076.77%	48,367 $375,000
Q1 2022 May 16, 2022	BUY	$15.0 - $15.4 $17,370 - $17,833	1,158 New	1,158 $17,000

Others Institutions Holding ANTX

# of Institutions

Shares Held

7.57M

Call Options Held

Put Options Held

View Full List

About AN2 Therapeutics, Inc.

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $22.1M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

More about ANTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account